SCIENCE NEWS More Prostate Cancer Diagnosed in Brothers: Study Men with a brother who has prostate cancer are more likely than other men to be diagnosed with the disease, but screening rather than genetics may be behind it, a new study suggests. [Press release from CBC News discussing online prepublication in the Journal of the National Cancer Institute]
Prostate Cancer Death Related to BCR, but Rare Outcome US research shows that biochemical recurrence (BCR) of prostate cancer after treatment is associated with prostate cancer mortality, although only a minority of elderly men with recurrence will die from the disease. [Press release from MedWire News discussing online prepublication in Archives of Internal Medicine] Finasteride Use Up in VHA System but Not for Prevention Finasteride prescriptions in the Veterans Health Administration (VHA) increased between 2000 and 2005, but the increase probably was not due to doctors prescribing it for prostate cancer chemoprevention, according to research. [Press release from Modern Medicine discussing online prepublication in Cancer Epidemiology, Biomarkers & Prevention] Prediction of Prostate Cancer Progression Possible with Hyperspectral Imaging A study conducted by scientists at ChemImage Corporation, in partnership with a well-known U.S. medical research and treatment center, revealed that Raman Molecular Imaging (RMI), a type of hyperspectral imaging, has great potential in predicting the progression of prostate cancer. [Press release from Chemimage Corporation discussing online prepublication in the British Journal of Urology International]  | CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Phosphorylation and Activation of Androgen Receptor by Aurora-A In this study, scientists demonstrate elevated levels of Aurora-A in androgen-refractory LNCaP-RF but not androgen-sensitive LNCaP cells, which prompted us to examine whether Aurora-A regulates androgen receptor and whether elevated Aurora-A is involved in androgen-independent cell growth. [J Biol Chem] Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer In this report, researchers demonstrate that both arginase 1 and arginase 2 are expressed by hormone-sensitive and hormone-refractory prostate cancer cell lines, with the LNCaP cells having the highest arginase activity. [PLoS ONE]
Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth Here investigators established a reporter system that monitors androgen receptor-mediated activation of a prostate specific antigen promoter. [Mol Pharmacol] Inactivation of the WASF3 Gene in Prostate Cancer Cells Leads to Suppression of Tumorigenicity and Metastases The WASF3 protein is involved in cell movement and invasion, and to investigate its role in prostate cancer progression scientists studied the phenotypic effects of knockdown in primary tumors and cell lines. [Br J Cancer] Epigenetic Silencing of SOCS3 Identifies a Subset of Prostate Cancer with an Aggressive Behavior The data suggest that suppressor of cytokine signaling 3 (SOCS3) hypermethylation may be involved in the pathogenesis of prostate cancer and could identify a tumor subset with an aggressive behavior. [Prostate] Statins Reduce the Androgen Sensitivity and Cell Proliferation by Decreasing the Androgen Receptor Protein in Prostate Cancer Cells In the present study, scientists determined the molecular mechanisms related to the regulation of prostate-specific antigen, androgen receptor and cell proliferation in prostate cancer cell lines by statins. [Prostate] Type-1 Polarized Dendritic Cells Loaded with Apoptotic Prostate Cancer Cells are Potent Inducers of CD8+ T Cells Against Prostate Cancer Cells and Defined Prostate Cancer-Specific Epitopes In order to develop improved vaccines for patients with recurrent prostate cancer (PCa), investigators tested the feasibility of using type-1 polarized dendritic cells to cross-present antigens from allogeneic PCa cells and to induce functional CD8+ T cell responses against PCa cells and against defined MHC class I-restricted PCa-relevant epitopes. [Prostate] CLINICAL RESEARCH Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. [J Natl Cancer Inst] Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans To describe patterns of biochemical recurrence and subsequent mortality, researchers conducted an observational study in a community-based, “high-comorbidity” setting of 623 US veterans diagnosed as having prostate cancer from 1991 to 1995 and receiving radical prostatectomy or radiation therapy. [Arch Intern Med] Knowledge and Use of Finasteride for the Prevention of Prostate Cancer Investigators examined the influence of the Prostate Cancer Prevention Trial on finasteride prescribing within the Veterans Health Administration. [Cancer Epidemiol Biomarkers Prev] Raman Spectral Imaging of Prostate Cancer: Can Raman Molecular Imaging be Used to Augment Standard Histopathology? The purpose of the study is to evaluate whether Raman molecular imaging (which combines digital imaging and analytical spectroscopy to evaluate the biochemical composition of interrogated material) can be used to identify biochemical differences in patients with Gleason 7 prostate cancer who progress to metastatic disease and die from prostate cancer. [BJU Int] Metronomic Administration of Zoledronic Acid and Taxotere Combination in Castration Resistant Prostate Cancer Patients. Phase I ZANTE Trial Twenty-two patients enrolled into the study (median age: 73 years; range: 43-80) received one of three escalated doses of docetaxel (DTX) [30, 40 and 50mg/m(2)] in combination with a fixed dose of zoledronic acid (ZOL) (2mg), both administered every 14 days in two different sequences: DTX at the day 1 followed by ZOL at the day 2 (sequence A) or the reverse (sequence B). Patients were evaluated for adverse events and serum IL-8, MMP-2 and MMP-9 were evaluated prior and after therapy with the two sequences of administration of DTX and ZOL. [Cancer Biol Ther] Incidence of Insignificant Prostate Cancer Using Free/Total PSA: Results of a Case-Finding Protocol on 14453 Patients The aim of this study is to evaluate prostate cancer (PCa) detection and incidence of pathologically insignificant PCa (pIPCa) tumour using percent-free PSA (%f-PSA) in patients with total PSA less than or equal to 10 ng/ml. [Prostate Cancer Prostatic Dis] | POLICY NEWS Human Genetics Commission Sets New Standards for Direct-to-Consumer Genetic Tests The Common Framework of Principles for direct-to-consumer genetic testing services, published by the Human Genetics Commission, aims to ensure that people who choose to buy genetic tests themselves can have confidence that the companies selling them follow basic principles of consent, data protection, truth in marketing, scientific rigor and balanced interpretation. [Human Genetics Commission, United Kingdom] EU Agency Allows Access to Drug Side Effects Data The European Medicines Agency has agreed to provide access to studies about drug side effects, following criticism over data secrecy from the European Ombudsman. [European Medicines Agency, European Union] University of California, Berkeley Alters DNA Testing Program The California Department of Public Health has instructed the University of California, Berkeley, not to proceed with a portion of its ground-breaking program to educate students about genetic testing and personalized medicine. [California Department of Public Health, United States] Comprehensive List of Guidance Documents at the Food and Drug Administration [Docket No. FDA-1998-N-0050] (formerly Docket No. 1998N-0046) [Food and Drug Administration, United States] Proposed Collection; Comment Request; NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI) (FR Doc. 2010-20167) [National Institutes of Health, United States] National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-19939) [National Institutes of Health, United States] 7342.007 Addendum – Imported Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) [Center for Biologics Evaluation and Research, United States] | EVENTS (Listed by Date) Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA) August 23-27, 2010 Toronto, Canada Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences 2nd Annual World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland The Science of Global Prostate Cancer Disparities in Black Men August 27-29, 2010 Jacksonville, United States 28th World Congress of Endourology and SWL September 1-4, 2010 Chicago, United States Prostate Cancer Research Institute Conference 2010 September 11-12, 2010 Los Angeles, United States International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010 September 15-17, 2010 Sydney, Australia 2010 Prostate Cancer Canada (PCCN) Conference September 22-25, 2010 Toronto, Canada International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations September 27-28, 2010 San Francisco, United States 35th European Society for Medical Oncology (ESMO) Congress October 8–12, 2010 Milan, Italy Frontiers in Tumour Progression October 24-27, 2010 Madrid, Spain Cancer Pharmacogenetics: Personalising Medicine November 22-24, 2010 Madrid, Spain NEW IMPaCT: Innovative Minds in Prostate Cancer Today 2011 March 9-12, 2011 Orlando, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Cell Therapy Technologist (Opexa Therapeutics) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News. Visit here to post your career opportunities. Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. | | |